Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence
- 5 October 2023
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 29 (11) , 2748-2752
Abstract
Pre-exposure prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate and emtricitabine administered orally daily is effective in preventing human immunodeficiency virus (HIV) acquisition in both men and women with sufficient adherence; however, the adherence–efficacy relationship in cisgender women has not been well established. We calculated the adherence–efficacy curve for cisgender women by using HIV incidence and plasma TFV concentration data from three trials (FEM-PrEP, VOICE and Partners PrEP). We imputed TFV diphosphate (TFV-DP) concentrations, a measure of long-term adherence, from TFV quantification by using data from the HIV Prevention Trials Network 082 study, which measured both TFV-DP and TFV concentrations. Two, four and seven pills per week reduced HIV incidence by 59.3% (95% credible interval (CrI) 29.9–95.8%), 83.8% (95% CI 51.7–99.8%) and 95.9% (95% CI 72.6–100%), respectively. Our adherence–efficacy curve can be validated and updated by HIV prevention studies that directly measure TFV-DP concentrations. The curve suggests that high adherence confers high protection in cisgender women. However, the lower efficacy with partial adherence highlights the need for new PrEP products and interventions to increase adherence.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (UM1AI068617, UM1AI068617, UM1AI068617, UM1AI068619, UM1AI068617, UM1AI068617, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068617)
- U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (UM1AI068617, UM1AI068617, UM1AI068617, UM1AI068619, UM1AI068617, UM1AI068617, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068619, UM1AI068617)
This publication has 36 references indexed in Scilit:
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2015
- Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyThe Lancet Infectious Diseases, 2014
- HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV PreventionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2013
- Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with MenScience Translational Medicine, 2012
- Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in BotswanaNew England Journal of Medicine, 2012
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Preexposure Prophylaxis for HIV Infection among African WomenNew England Journal of Medicine, 2012
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010